Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. - Wikidata - wikimedia - TriplyDB

Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

http://www.wikidata.org/entity/Q37905034

about

New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.

P2860

Q37344050-FE82DA6B-83A7-4465-B635-305993DD31C9 Q40313702-ABC0B4BD-7E48-4034-986D-4B19FCB10B87

P2860

Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

http://www.wikidata.org/entity/Q37905034

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Clinical options after failure ...... with hematologic malignancies.

@en

Clinical options after failure ...... with hematologic malignancies.

@nl

type

label

Clinical options after failure ...... with hematologic malignancies.

@en

Clinical options after failure ...... with hematologic malignancies.

@nl

prefLabel

Clinical options after failure ...... with hematologic malignancies.

@en

Clinical options after failure ...... with hematologic malignancies.

@nl

P1433

Q37905034-7DEA58C8-9674-479C-A87E-F8DB53CADE8E

P1476

Q37905034-C46702C4-14BF-423C-9D5C-42F0D094C6A0

P2093

Q37905034-99507160-E47C-46B8-8F91-B9FE41F3DF95

Q37905034-D80F3BCC-5368-425D-8061-479E5140B5BF

P2860

Q37905034-04A34FF7-A80E-4CAF-B42D-2A8BD6B37FB4

Q37905034-05A2E9AD-4FFC-4D25-A757-637B2A2265EF

Q37905034-073E1E38-7719-45A4-B21D-0E8693C6BA79

Q37905034-07582346-6CD7-41E7-8E11-8C2090669957

Q37905034-07F4196D-F733-42F9-B9DF-EB3FC3C53268

Q37905034-094E19E4-741B-4C8D-9508-2C73E6733D90

Q37905034-0A4CA8EC-0F2F-452C-9122-20F6A9F37BB0

Q37905034-0C25BB36-3115-4A64-991C-F632E38198BE

Q37905034-0EA67D56-717A-44E8-AF34-1E53612F8998

Q37905034-13CC90D7-73F9-4AF3-96F7-9EECD5191756

P304

Q37905034-D47E5DA9-A706-4327-B470-916F70DB82CD

P31

Q37905034-379E1C6E-33F8-420A-BFE4-294E55648174

P356

Q37905034-FF898CA5-739E-4386-AFFF-654867F03BEE

P433

Q37905034-7498CF77-E9F3-477E-B9FB-DE4FD6C5D0FC

P478

Q37905034-471993D1-87DD-4A65-8B6E-BCB5647AB655

P577

Q37905034-1CE268C5-6C06-48D9-844E-0A17FBA3C642

P5875

Q37905034-09148C98-CD39-4651-9FCF-3250AACCCA2B

P698

Q37905034-EF0F4676-3868-440B-B42D-56355DB33FF3

P356

P1433

Expert Review of Clinical Immunology

P1476

Clinical options after failure ...... with hematologic malignancies.

@en

P2093

Aleksandra Petrovic

http://www.w3.org/2001/XMLSchema#string

Gregory Hale

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia

Bispecific T-cell engaging antibodies for cancer therapy

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation

P304

515-25; quiz 526-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECI.11.24

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51519325

http://www.w3.org/2001/XMLSchema#string

P698

21787195

http://www.w3.org/2001/XMLSchema#string